PD-L1 expression, TCGA subtype, and mutational load were independent predictors of atezolizumab response in patients with mUC, and response prediction improved significantly with combination of these markers.
Nivolumab treatment beyond progression associated with reduced tumor burden, improved OS, and lower incidence of all grade adverse events in patients with advanced RCC.
Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in heavily pretreated patients with metastatic urothelial carcinoma.
Patient-reported outcomes from CHAARTED indicate that adding docetaxel to ADT increased physical symptoms during first 3 months of treatment but was associated with significantly improved QoL at 12 mos in patients with mHSPC.
Cabazitaxel and docetaxel show similar clinical activity in mCRPC but with distinct safety profiles.
Results from this small exploratory study suggest that radium-223 retreatment is well tolerated and may help delay future bone events in patients with CRPC and bone metastases who experience radiographic or clinical progression following an initial course of radium-223.
Here are my thoughts on the abstracts from ASCO 2016 that have the most potential to change clinical practice.
In this activity, Daniel M. Geynisman, MD, and Brian Rini, MD, FACP, analyze and discuss the most clinically relevant data on the management of genitourinary cancers presented at the 2016 ASCO annual meeting.
Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in previously untreated, cisplatin-ineligible patients with advanced or metastatic urothelial carcinoma.
In this downloadable slideset, Daniel M. Geynisman, MD and Brian Rini, MD, review key data presented at the 2016 annual meeting of the American Society of Clinical Oncology.